Annayya R Aroor1, Guanghong Jia2, Javad Habibi2, Zhe Sun3, Francisco I Ramirez-Perez3, Barron Brady2, Dongqing Chen2, Luis A Martinez-Lemus4, Camila Manrique2, Ravi Nistala5, Adam T Whaley-Connell5, Vincent G Demarco6, Gerald A Meininger7, James R Sowers8. 1. Diabetes and Cardiovascular Research Center, Department of Medicine, University of Missouri Columbia, School of Medicine, Columbia, MO 65212, USA; Research Service Harry S Truman Memorial Veterans Hospital, University of Missouri School of Medicine, Columbia, MO 65212, USA. Electronic address: aroora@health.missouri.edu. 2. Diabetes and Cardiovascular Research Center, Department of Medicine, University of Missouri Columbia, School of Medicine, Columbia, MO 65212, USA; Research Service Harry S Truman Memorial Veterans Hospital, University of Missouri School of Medicine, Columbia, MO 65212, USA. 3. Dalton Cardiovascular Research Center, University of Missouri School of Medicine, Columbia, MO 65212, USA. 4. Department of Medical Pharmacology and Physiology, University of Missouri Columbia, School of Medicine, Columbia, MO 65212, USA; Dalton Cardiovascular Research Center, University of Missouri School of Medicine, Columbia, MO 65212, USA; Research Service Harry S Truman Memorial Veterans Hospital, University of Missouri School of Medicine, Columbia, MO 65212, USA. 5. Diabetes and Cardiovascular Research Center, Department of Medicine, University of Missouri Columbia, School of Medicine, Columbia, MO 65212, USA; Division of Nephrology and Hypertension, Department of Medicine, University of Missouri Columbia, School of Medicine, Columbia, MO 65212, USA; Research Service Harry S Truman Memorial Veterans Hospital, University of Missouri School of Medicine, Columbia, MO 65212, USA. 6. Diabetes and Cardiovascular Research Center, Department of Medicine, University of Missouri Columbia, School of Medicine, Columbia, MO 65212, USA; Department of Medical Pharmacology and Physiology, University of Missouri Columbia, School of Medicine, Columbia, MO 65212, USA; Research Service Harry S Truman Memorial Veterans Hospital, University of Missouri School of Medicine, Columbia, MO 65212, USA. 7. Department of Medical Pharmacology and Physiology, University of Missouri Columbia, School of Medicine, Columbia, MO 65212, USA; Dalton Cardiovascular Research Center, University of Missouri School of Medicine, Columbia, MO 65212, USA. 8. Diabetes and Cardiovascular Research Center, Department of Medicine, University of Missouri Columbia, School of Medicine, Columbia, MO 65212, USA; Department of Medical Pharmacology and Physiology, University of Missouri Columbia, School of Medicine, Columbia, MO 65212, USA; Research Service Harry S Truman Memorial Veterans Hospital, University of Missouri School of Medicine, Columbia, MO 65212, USA. Electronic address: sowersj@health.missouri.edu.
Abstract
OBJECTIVE: Aortic vascular stiffness has been implicated in the development of cardiovascular disease (CVD) and chronic kidney disease (CKD) in obese individuals. However, the mechanism promoting these adverse effects are unclear. In this context, promotion of obesity through consumption of a western diet (WD) high in fat and fructose leads to excess circulating uric acid. There is accumulating data implicating elevated uric acid in the promotion of CVD and CKD. Accordingly, we hypothesized that xanthine oxidase(XO) inhibition with allopurinol would prevent a rise in vascular stiffness and proteinuria in a translationally relevant model of WD-induced obesity. MATERIALS/ METHODS: Four-week-old C57BL6/J male mice were fed a WD with excess fat (46%) and fructose (17.5%) with or without allopurinol (125mg/L in drinking water) for 16weeks. Aortic endothelial and extracellular matrix/vascular smooth muscle stiffness was evaluated by atomic force microscopy. Aortic XO activity, 3-nitrotyrosine (3-NT) and aortic endothelial sodium channel (EnNaC) expression were evaluated along with aortic expression of inflammatory markers. In the kidney, expression of toll like receptor 4 (TLR4) and fibronectin were assessed along with evaluation of proteinuria. RESULTS: XO inhibition significantly attenuated WD-induced increases in plasma uric acid, vascular XO activity and oxidative stress, in concert with reductions in proteinuria. Further, XO inhibition prevented WD-induced increases in aortic EnNaC expression and associated endothelial and subendothelial stiffness. XO inhibition also reduced vascular pro-inflammatory and maladaptive immune responses induced by consumption of a WD. XO inhibition also decreased WD-induced increases in renal TLR4 and fibronectin that associated proteinuria. CONCLUSIONS: Consumption of a WD leads to elevations in plasma uric acid, increased vascular XO activity, oxidative stress, vascular stiffness, and proteinuria all of which are attenuated with allopurinol administration.
OBJECTIVE: Aortic vascular stiffness has been implicated in the development of cardiovascular disease (CVD) and chronic kidney disease (CKD) in obese individuals. However, the mechanism promoting these adverse effects are unclear. In this context, promotion of obesity through consumption of a western diet (WD) high in fat and fructose leads to excess circulating uric acid. There is accumulating data implicating elevated uric acid in the promotion of CVD and CKD. Accordingly, we hypothesized that xanthine oxidase(XO) inhibition with allopurinol would prevent a rise in vascular stiffness and proteinuria in a translationally relevant model of WD-induced obesity. MATERIALS/ METHODS: Four-week-old C57BL6/J male mice were fed a WD with excess fat (46%) and fructose (17.5%) with or without allopurinol (125mg/L in drinking water) for 16weeks. Aortic endothelial and extracellular matrix/vascular smooth muscle stiffness was evaluated by atomic force microscopy. Aortic XO activity, 3-nitrotyrosine (3-NT) and aortic endothelial sodium channel (EnNaC) expression were evaluated along with aortic expression of inflammatory markers. In the kidney, expression of toll like receptor 4 (TLR4) and fibronectin were assessed along with evaluation of proteinuria. RESULTS:XO inhibition significantly attenuated WD-induced increases in plasma uric acid, vascular XO activity and oxidative stress, in concert with reductions in proteinuria. Further, XO inhibition prevented WD-induced increases in aortic EnNaC expression and associated endothelial and subendothelial stiffness. XO inhibition also reduced vascular pro-inflammatory and maladaptive immune responses induced by consumption of a WD. XO inhibition also decreased WD-induced increases in renal TLR4 and fibronectin that associated proteinuria. CONCLUSIONS: Consumption of a WD leads to elevations in plasma uric acid, increased vascular XO activity, oxidative stress, vascular stiffness, and proteinuria all of which are attenuated with allopurinol administration.
Authors: Jorge A Castorena-Gonzalez; Marius C Staiculescu; Christopher A Foote; Luis Polo-Parada; Luis A Martinez-Lemus Journal: Am J Physiol Heart Circ Physiol Date: 2013-12-13 Impact factor: 4.733
Authors: Claudio Borghi; Enrico Agabiti Rosei; Thomas Bardin; Jesse Dawson; Anna Dominiczak; Jan T Kielstein; Athanasios J Manolis; Fernando Perez-Ruiz; Giuseppe Mancia Journal: J Hypertens Date: 2015-09 Impact factor: 4.844
Authors: Vincent G DeMarco; Javad Habibi; Guanghong Jia; Annayya R Aroor; Francisco I Ramirez-Perez; Luis A Martinez-Lemus; Shawn B Bender; Mona Garro; Melvin R Hayden; Zhe Sun; Gerald A Meininger; Camila Manrique; Adam Whaley-Connell; James R Sowers Journal: Hypertension Date: 2015-05-26 Impact factor: 10.190
Authors: Johannes Fels; Pia Jeggle; Ivan Liashkovich; Wladimir Peters; Hans Oberleithner Journal: Cell Tissue Res Date: 2014-03-19 Impact factor: 5.249
Authors: Jaume Padilla; Makenzie L Woodford; Guido Lastra-Gonzalez; Vanesa Martinez-Diaz; Shumpei Fujie; Yan Yang; Alexandre M C Lising; Francisco I Ramirez-Perez; Annayya R Aroor; Mariana Morales-Quinones; Thaysa Ghiarone; Adam Whaley-Connell; Luis A Martinez-Lemus; Michael A Hill; Camila Manrique-Acevedo Journal: Endocrinology Date: 2019-12-01 Impact factor: 4.736
Authors: Neekun Sharma; Rishabh Dev; Anthony M Belenchia; Annayya R Aroor; Adam Whaley-Connell; Lakshmi Pulakat; Chetan P Hans Journal: Arterioscler Thromb Vasc Biol Date: 2019-02 Impact factor: 8.311
Authors: Zachary I Grunewald; Francisco I Ramirez-Perez; Makenzie L Woodford; Mariana Morales-Quinones; Salvador Mejia; Camila Manrique-Acevedo; Ulrich Siebenlist; Luis A Martinez-Lemus; Bysani Chandrasekar; Jaume Padilla Journal: Hypertension Date: 2020-08-24 Impact factor: 10.190